Table 2.

Cohort characteristics for human organoid-based studies [related to Figs. 4 and 5A, Main Text].

Internal number (UC San Diego HUMANOID)	% TEER increase after PF, normalized to untreated (Average from 3–5 experiments)	Disease location; Disease behavior	Drug history	Disease duration (years)	Disease scorea SES
Healthy H4	52.1	n/a	n/a	n/a	n/a
Healthy H9	17.5	n/a	n/a	n/a	n/a
Healthy H12	9	n/a	n/a	n/a	n/a
Healthy H13	6.8	n/a	n/a	n/a	n/a
UC1	30	Pancolitis	Current Adalimumab	9	8
UC2	100	Left sided colitis	Only ASA	21	9
UC3	62	Left sided colitis	Infliximab (just started)	3	6
UC13	187.5	Proctitis	Vedolizumab	0.28	5
CD2	37	Ileocolitis	Current Remicade	2.8	Unk
CD3	18	Ileitis	Current Humira	3	Unk
CD10	49.45	Ileitis; Non-stricturing, non-penetrating	Current Adalimumab Past infliximab	23	8
CD11	55.5	Ileocolitis; Stricturing	Past Vedolizumab, Past Adalimumab	19	6
CD20	47.3	Ileitis; Non-stricturing, non-penetrating	Current Adalimumab	1	0
CD24	15.3	Colitis; Stricturing	Current Vedolizumab	6	0
CD30	377.5	Ileitis; Non-stricturing, non-penetrating	Naive	18	0
CD21	211.4	Colitis; Non-stricturing; non-penetrating	Current Infliximab	1	8
CD32	52.9	Ileocolitis; Penetrating	Current Infliximab	20	3
CD42	3.3	Ileocolitis; Penetrating	Past Infliximab	12	4

In 18 human subjects in the cohort, 11 are Male, 7 are Female from the following age group: below 20 years: 3; 21–40 years: 10; above 40 years: 5.

Diseased Cohort (N = 14).

Increase in TEER less than ≤25% N = 3 of 14; 21.42% (all CD).

Increase in TEER within >25–75%, N = 7 of 14; 50% (5 CD, 2 UC).

Increase in TEER is above >75%, N = 4 of 14; 28.57% (2 CD, 2 UC).

Unk unknown; n/a not available.

^aDisease Score: UC: Histo Geboes Score, CD: SES-CD score/Disease score.